Uganda - English - National Drug Authority

galentic pharma ltd - selenium sulfide - topical external suspensions - 2.5% w/v

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

gladron chemicals sdn bhd - selenium sulfide -

United States - English - NLM (National Library of Medicine)

viona pharmaceuticals inc - ranolazine (unii: a6iez5m406) (ranolazine - unii:a6iez5m406) - ranolazine extended-release tablet is indicated for the treatment of chronic angina. ranolazine extended-release tablet may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers. ranolazine is contraindicated in patients: - taking strong inhibitors of cyp3a [seedrug interactions (7.1)] - taking inducers of cyp3a [see drug interactions (7.1)] - with liver cirrhosis [see use in specific populations (8.6)] risk summary there are no available data on ranolazine use in pregnant women to inform any drug-associated risks. studies in rats and rabbits showed no evidence of fetal harm at exposures 4 times the maximum recommended human dose (mrhd) (see data). in the u.s. general population, the estimated background risk of major birth defects and of miscarriage of clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data embryofetal toxicity studies were conducted in rats and ra

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - ranolazine (unii: a6iez5m406) (ranolazine - unii:a6iez5m406) - ranolazine extended-release tablet is indicated for the treatment of chronic angina. ranolazine extended-release tablet may be used with beta-blockers, nitrates, calcium channel blockers, anti-platelet therapy, lipid-lowering therapy, ace inhibitors, and angiotensin receptor blockers. ranolazine is contraindicated in patients: - taking strong inhibitors of cyp3a [seedrug interactions (7.1)] - taking inducers of cyp3a [see drug interactions (7.1)] - with liver cirrhosis [see use in specific populations (8.6)] risk summary there are no available data on ranolazine use in pregnant women to inform any drug-associated risks. studies in rats and rabbits showed no evidence of fetal harm at exposures 4 times the maximum recommended human dose (mrhd) (see data). in the u.s. general population, the estimated background risk of major birth defects and of miscarriage of clinically recognized pregnancies is 2-4% and 15-20%, respectively. data animal data embryofetal toxicity studies were conducted in rats and ra

Singapore - English - HSA (Health Sciences Authority)

bio-rad laboratories (singapore) pte ltd - clinical toxicology - the tox/see™ drug screen test is a lateral flow chromatographic immunoassay for the qualitative detection of multiple drugs and drug metabolites in urine.

United States - English - NLM (National Library of Medicine)

mckesson contract packaging - carvedilol (unii: 0k47ul67f2) (carvedilol - unii:0k47ul67f2) - carvedilol 3.125 mg

United States - English - NLM (National Library of Medicine)

atlantic biologicals corps - phenobarbital (unii: yqe403bp4d) (phenobarbital - unii:yqe403bp4d) - - sedative - anticonvulsant–for the treatment of generalized and partial seizures. phenobarbital is contraindicated in patients who are hypersensitive to barbiturates, in patients with a history of manifest or latent porphyria, and in patients with marked impairment of liver function or respiratory disease in which dyspnea or obstruction is evident. controlled substance–phenobarbital is a schedule iv drug. dependence–barbiturates may be habit forming. tolerance, psychological dependence, and physical dependence may occur, especially following prolonged use of high doses of barbiturates. daily administrations in excess of 400 mg of pentobarbital or secobarbital for approximately 90 days is likely to produce some degree of physical dependence. a dosage of 600 to 800 mg taken for at least 35 days is sufficient to produce withdrawal seizures. the average daily dose for the barbiturate addict is usually about 1.5 g. as tolerance to barbiturates develops, the amount needed to maintain the same level of intoxication

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline consumer healthcare sdn. bhd. - paracetamol; phenylephrine hcl; chlorpheniramine maleate -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline consumer healthcare sdn. bhd. - paracetamol; caffeine -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

glaxosmithkline consumer healthcare sdn. bhd. - pamabrom; paracetamol -